Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.650 -0.060 (-3.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – 
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Participate in Upcoming Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.